Gen-Probe Incorporated
Medical Devices & Tech
10210 Genetic Center Drive
San Diego, CA 92121 USA
phone: (858) 410-8000
fax: (800) 288-3141
Symbol GPRO
Exchange NASDAQ
Founded 0
Employees
www.gen-probe.com/
Research Sector Medical Devices & Tech
Summary Description
Cost-effective nucleic acid probe-based products.
Management
Henry L. Nordhoff, Chairman, President and Chief Executive Officer; Lyle J. Arnold, Ph.D., Vice President, Research; R. William Bowen, Vice President & General Counsel; Niall M. Conway, Executive Vice President, Operations; Valerie M. Day, Vice President, Product Development; Diana De Walt, Vice President, Human Resources; Martin B. Edelshain, Vice President, Strategic Planning & Business Development; Paul Gargan, Ph.D., Vice President, Business Development; Daniel L. Kacian, Ph.D., M.D., Executive Vice President and Chief Scientist; Stephen J. Kondor, Vice President Sales & Marketing; Gurney Lashley, Vice President, Supply Chain; Lynda A. Merrill, Vice President, Industrial Relationships; Larry Mimms, Ph.D., Executive Vice President, Research and Development; Herm Rosenman, Vice President, Finance and Chief Financial Officer; Don Tartre, Vice President, Finance & Corporate Controller
Ownership
Financials Mkt Cap :2


* numbers in thousands

 
Keywords
cost-effective, nucleic, acid, probe-based, products, urology, advamed

Comment | Printable Version | Oct. 01, 2008
If you work for Gen-Probe Incorporated and want to update this profile, click here


Description
Gen Probe Incorporated is engaged in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood. The Company has received Food and Drug Administration (FDA) approvals for more than 50 products that detect various infectious microorganisms. In February 2002, the FDA approved the Biologics License Application (BLA) for the biochemical test (assay) used to screen donated blood for human immunodeficiency virus (type 1) (HIV-1) and hepatitis C virus (HCV). At the time, the assay was the only FDA-approved NAT assay available for screening donated blood and is utilized to screen over 72% of the United States donated blood supply for HIV-1 and HCV.


2008-10-11-999